Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 30, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions
Gastric AdenocarcinomaGastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal CarcinomaPeritoneal Metastasis
Interventions
DRUG

Tislelizumab

recombinant humanized anti-PD-1 monoclonal antibody for injection; 200mg ivdrip,d1, q3w

DRUG

S-1

40\~60mg Bid,d1\~14, q3w

DRUG

Oxaliplatin

130mg/m2,iv drip for 2h,d1, q3w

DRUG

Docetaxel

Docetaxel at a dose of 20 mg/m2 or paclitaxel at a dose of 40 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)

DRUG

Paclitaxel

Paclitaxel at a dose of 40 mg/m2 or docetaxel at a dose of 20 mg/m2 dissolved in 3-5 L of normal saline heated to 43 ± 0.5 °C for HIPEC.(d01-d03,qd,before first cycle of Tislelizumab and SOX)

All Listed Sponsors
lead

Fudan University

OTHER